Intimation of receipt of approval for biosimilar Dyrupeq from UK''s MHRA by Curateq Biologics s.r.o, a wholly owned step down subsidiary of the Company.
Awaiting price reaction for this filing.
Aurobindo Pharma's wholly owned step-down subsidiary CuraTeQ Biologics s.r.o. has received marketing authorization from the UK's MHRA for Dyrupeg™, its pegylated filgrastim biosimilar used to boost white blood cell counts in patients undergoing chemotherapy. This follows Dyrupeg's earlier EU approval from the European Commission in April 2025. Dyrupeg is CuraTeQ's third biosimilar approved by MHRA, after Bevqolva™ (December 2024) and Zefylti™ (May 2025), showing a steady pipeline of regulatory wins in advanced markets.
This UK approval expands Aurobindo's biosimilars footprint in a key regulated market and reinforces the credibility of its biologics pipeline, potentially supporting future revenue from the UK and other MHRA-recognized markets.